GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results

Up to 63.7% Reduction in Bone Marrow Blast Levels Restores Patient’s Endogenous…

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference

BEVERLY HILLS, Calif., March 10, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

BEVERLY HILLS, Calif., March 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

Personalized Medicine Is The Next Big Trend For Biotech Stocks & 1 Company Could Radically Disrupt The Industry

Personalized Medicine Should Be At The Top Of Your List In 2021 & Here’s Why

GT Biopharma Adds University of Wisconsin–Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment

BEVERLY HILLS, Calif., March 4, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…